对有支气管肺发育不良风险并接受地塞米松治疗的极早产儿的安慰剂对照、随机GH实验
A randomized, placebo-controlled GH trial in very preterm infants who were at risk for bronchopulmonary dysplasia and were treated with dexamethasone作者机构：Department of Pediatrics Sint Franciscus Gasthuis Kleiweg 500 3004 BA Rotterdam Netherlands.Dr
出 版 物：《世界核心医学期刊文摘（儿科学分册）》 (Dkgest of the World Latest Medical Information)
年 卷 期：2006年第2卷第4期
页 面：60-61页
学科分类：1002[医学-临床医学] 100202[医学-儿科学] 10[医学]
主 题：GH 安慰剂对照 DEXA 远期影响 生长抑制作用 头围 人工通气 发育障碍 发育状况 分解代谢
摘 要：Very preterm infants who develop bronchopulmonarydysplasia are often treated with dexamethasone (DEXA) to wean them from the ventilator. As DEXA has growth-supp-ressive and catabolic effects, which might have long-term consequences on growth and organ development, we investigated whether high-dose GH treatment could overcome these effects. In a randomized, double-blind, placebo-controlled trial, 30 ventilated very low birth weight infants were assigned to receive either GH or placebo treatment after start of DEXA. DEXA was given for 24 d (starting dose 0.5 mg· kg- 1· d- 1, tapering off every third day). Simultaneously, high-dose GH (0.3 mg· kg- 1· d- 1) or placebo was administered during 6 wk. During high-dose DEXA treatment (dose 0.5- 0.3 mg· kg- 1· d- 1), no gain in head circumference, weight, crown-heel length, and knee-heel length occurred in the GH and placebo groups. Growth during the 6- wk study period was not different between the GH and the placebo groups. Two patients in the placebo group died, but the number and the severity of adverse effects was not statistically different between the GH and placebo groups. In conclusion, high-dose GH treatment did not improve growth in DEXAtreated very preterm infants and thus cannot be recommended to prevent growth failure in these infants. During high-dose DEXA, a complete growth arrest occurred, including stunting of head growth. Growth in head circumference and weight with lower dose DEXA was comparable to growth after discontinuation of DEXA.
维普期刊数据库
同方期刊数据库